Discontinued — last reported Q3 '24
Products & Services · Transactional price remaining performance obligation
Roche License Obligation — Transactional price remaining performance obligation
Alnylam Pharmaceuticals Roche License Obligation — Transactional price remaining performance obligation remained flat by 0.0% to $375M in Q3 2024 compared to the prior quarter.
Analysis
Metric ID:
alny_segment_roche_license_obligation_transactional_price_remaining_performance_obligationHistorical Data
3 periods
| Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|
| Value | $375M | $375M | $375M |
| QoQ Change | — | +0.0% | +0.0% |
Range$375M – $375M
Current Streak2+ quarters growth
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's roche license obligation — transactional price remaining performance obligation?
- Alnylam Pharmaceuticals (ALNY) reported roche license obligation — transactional price remaining performance obligation of $375M in Q3 2024.